The two updates underscore Teva’s strong execution of its Pivot to Growth strategy and commitment to financial ...

When patent protection on drugs ends, however, companies face generic competition, as competitors such as Teva make copies of ...

Teva stock climbs past $30 with strong Austedo and Ajovy sales, but shifting Wall Street sentiment may affect its outlook.

S&P upgraded Teva to BB+ and Moody's turned positive, citing falling leverage, stronger cash flow, and branded drug momentum that could support a future investment-grade rating.

Teva Pharmaceuticals USA has issued a nationwide recall of hundreds of thousands of bottles of a commonly prescribed blood ...

Teva Pharmaceutical Indus (NYSE: TEVA) has outperformed the market over the past 5 years by 13.95% on an annualized basis producing an average annual return of 27.15%. Currently, Teva Pharmaceutical ...

Teva Pharmaceutical is a leader in generic drugs, but these struggling makers of branded drugs may be a better choice.

A federal lawsuit seeking class-action status alleges that an antitrust scheme to delay releasing generic drugs originated in ...

The Federal Trade Commission announced on Wednesday that Teva Pharmaceutical (TEVA), under pressure from the agency, has requested the removal of more than 200 patents improperly listed in the FDA’s ...

Investing.com -- S&P Global Ratings has upgraded Teva Pharmaceutical Industries Ltd. to ’BB+’ from ’BB’ with a stable outlook ...

After pressure from the FTC, Teva has asked the FDA to delist hundreds of patents on products for asthma, diabetes, chronic obstructive pulmonary disease and for epinephrine autoinjectors, the agency ...

In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on Teva's website at: ...